FindTrial
Sign In

CDX-0159

DRUG5 trials

Sponsors

Celldex Therapeutics

Conditions

Cholinergic UrticariaChronic Spontaneous UrticariaCold Contact UrticariaCold UrticariaHealthy SubjectsPrurigo NodularisSymptomatic DermatographismSymptomatic Dermographism

Phase 1

A Phase 1 Study of CDX-0159
CompletedNCT04146129
Celldex TherapeuticsHealthy Subjects
Start: 2019-10-29End: 2020-06-26Updated: 2020-07-07
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
CompletedNCT04538794
Celldex TherapeuticsChronic Spontaneous Urticaria
Start: 2020-09-24End: 2023-01-17Updated: 2023-07-19
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
CompletedNCT04548869
Celldex TherapeuticsCholinergic Urticaria, Cold Contact Urticaria, Cold Urticaria +2
Start: 2020-11-24End: 2023-05-12Updated: 2023-05-17
A Study of CDX-0159 in Patients With Prurigo Nodularis
CompletedNCT04944862
Celldex TherapeuticsPrurigo Nodularis
Start: 2021-11-08End: 2023-07-31Updated: 2023-08-14
A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
CompletedNCT05031624
Celldex TherapeuticsHealthy Subjects
Start: 2021-08-30End: 2022-01-14Updated: 2022-01-21

Related Papers

Anti‐<scp>KIT</scp> Barzolvolimab for Chronic Spontaneous Urticaria
Allergy2025-05-269 citations